SCHEMBL7020873

SCHEMBL7020873

O=C(NCCc1c[nH]c2ccc(O)cc12)C1CCC1

nearest known ligand 0.91

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SPR P35270 4/20 0.91
MTNR1A P48039 3/20 0.72
ALDH1A1 P00352 3/20 0.66
KDM4E B2RXH2 3/20 0.66
NPSR1 Q6W5P4 2/20 0.66
CYP2D6 P10635 2/20 0.66
CYP1A2 P05177 1/20 0.66
CYP3A4 P08684 1/20 0.66
MAPT P10636 1/20 0.66
IDO1 P14902 1/20 0.66
HPGD P15428 1/20 0.66
BLM P54132 1/20 0.66
NOTUM Q6P988 1/20 0.66
MTNR1B P49286 1/20 0.65
TRPV1 Q8NER1 4/20 0.58
PTGS1 P23219 1/20 0.58
PTGS2 P35354 1/20 0.58
LMNA P02545 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
MEN1 O00255 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25234184 0.96 SPR (0.89) SPRMTNR1AALDH1A1KDM4ENPSR1
SCHEMBL30274816 0.96 SPR (0.89) SPRMTNR1AALDH1A1KDM4ENPSR1
SCHEMBL9123061 0.95 SPR (1.00) SPRMTNR1AALDH1A1KDM4ENPSR1
SCHEMBL9192809 0.84 MTNR1A (0.92) SPRMTNR1AALDH1A1KDM4ECYP2D6
SCHEMBL14584189 0.83 SPR (0.76) SPRMTNR1AALDH1A1KDM4ENPSR1
SCHEMBL7024067 0.82 MTNR1A (0.70) SPRMTNR1AALDH1A1KDM4EMAPT
SCHEMBL17913885 0.82 KDM4E (0.76) SPRMTNR1AALDH1A1KDM4ENPSR1
SCHEMBL1960963 0.81 SPR (0.78) SPRALDH1A1KDM4ENPSR1CYP2D6
SCHEMBL11468610 0.81 MTNR1A (0.97) SPRMTNR1AALDH1A1CYP1A2MAPT
SCHEMBL25076869 0.80 HTR2C (0.63) SPRALDH1A1KDM4ENPSR1CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6635650-B2 Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders LES LABORATOIRES SERVIER (FR) 2003-10-21 US disclosed
EP-1038863-B1 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof SERVIER LAB (FR) 2003-06-04 EP disclosed
EP-1057826-B1 Substituted dimeric carboxamide derivatives, method for preparing them, and pharmaceutical compositions containing them SERVIER LAB (FR) 2003-04-16 EP disclosed
US-20020035114-A1 Substituted dimeric compounds LESIEUR DANIEL (FR) 2002-03-21 US disclosed
US-6319930-B1 CONTAINING FUSED AROMATIC CARBO- OR HETEROCYCLIC RINGS AND AMIDE, THIOAMIDE, UREA OR THIOUREA GROUPS; USEFUL IN TREATING OR IN PREVENTING MELATONINERGIC DISORDERS. ADIR ET COMPAGNIE (FR) 2001-11-20 US disclosed
US-6310074-B1 TREATING MELATONINERGIC DISORDERS ADIR ET COMPAGNIE (FR) 2001-10-30 US disclosed
EP-1057826-A1 Substituted dimeric carboxamide derivatives, method for preparing them, and pharmaceutical compositions containing them ADIR ET COMPAGNIE (FR) 2000-12-06 EP disclosed
EP-1038863-A2 Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof ADIR ET COMPAGNIE (FR) 2000-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035114-A1 Substituted dimeric compounds NR0B2, NR0B1, NR2C2 SPR 2295/4885MTNR1A 4/4885ALDH1A1 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.